IV vs Oral vs Nasal Ketamine: Comparing Treatment Methods

Why the Method of Administration Matters

When people begin researching ketamine therapy, one of the first and most important questions they encounter is: which method of administration is right for me? The answer is not straightforward, because each delivery route offers a fundamentally different experience in terms of how the medication reaches the brain, how much of it gets there, how quickly effects begin, and what the overall treatment experience looks like.

Ketamine is available through several administration routes, but the three most common for psychiatric and pain applications are intravenous (IV) infusion, oral and sublingual formulations, and intranasal delivery. Each has distinct advantages and limitations, and understanding these differences is essential for making an informed treatment decision.

This guide provides a detailed, evidence-based comparison of these three primary methods to help you understand the tradeoffs involved.

Bioavailability: The Foundation of Comparison

Bioavailability refers to the percentage of an administered drug that actually reaches the bloodstream and is available to produce its intended effect. This single metric explains much of the difference between ketamine delivery methods.

These differences in bioavailability have practical implications. A patient who swallows a 200 mg oral dose of ketamine may absorb only 35-48 mg into the bloodstream, while the same amount delivered intravenously would deliver the full 200 mg. This is why dosing varies significantly across administration routes — the doses are calibrated to account for these absorption differences.

IV Ketamine Infusion

How It Works

Intravenous infusion delivers ketamine directly into the bloodstream through an IV line, bypassing all absorption barriers. The medication is typically dissolved in a normal saline solution and administered using an infusion pump that controls the delivery rate precisely.

The standard psychiatric protocol, established in the landmark Yale studies and replicated across hundreds of clinical trials, involves 0.5 mg/kg of body weight infused over 40 minutes.

Advantages

Highest bioavailability and precision. With 100% bioavailability, IV infusion delivers the exact intended dose with no absorption variability. Clinicians can adjust the infusion rate in real time based on patient response, slowing down if side effects are too intense or speeding up if tolerated well.

Most extensive evidence base. The overwhelming majority of published clinical trials on ketamine for depression, anxiety, and PTSD have used IV infusion. This means the efficacy data, safety data, and dosing protocols are most well-established for this route.

Rapid onset and predictable response. Effects begin within minutes, and the clinical team can observe the full response during the appointment. This predictability allows for more precise treatment adjustments over the course of a treatment series.

Clinical monitoring. IV infusion is administered in a clinical setting with continuous monitoring of vital signs, including blood pressure, heart rate, and oxygen saturation. A clinician is present throughout the session, allowing immediate intervention if needed.

Disadvantages

Cost. IV infusion is typically the most expensive method per session, ranging from $400 to $800 per treatment. The initial six-session series can cost $2,400 to $4,800. Most insurance plans do not cover off-label IV ketamine for psychiatric use.

Inconvenience. Patients must travel to a clinic for each session, which typically requires 1.5 to 2.5 hours including preparation, the 40-minute infusion, and recovery time. A companion must provide transportation home.

IV access. Some patients find needle insertion uncomfortable, and establishing IV access can occasionally be difficult in patients with small or difficult-to-access veins.

Limited availability. Depending on geographic location, specialized ketamine infusion clinics may not be conveniently accessible.

Oral and Sublingual Ketamine

How It Works

Oral and sublingual ketamine refers to compounded formulations prepared by specialty pharmacies, typically in the form of troches (lozenges), rapid-dissolve tablets, or liquid solutions. Sublingual administration involves holding the medication under the tongue for 10-15 minutes to allow absorption through the mucous membranes, while oral administration involves swallowing the medication for absorption through the gastrointestinal tract.

Most at-home ketamine programs prescribe sublingual formulations because the sublingual route achieves higher bioavailability (25-35%) than the oral route (17-24%).

Advantages

Accessibility. Oral and sublingual ketamine can be prescribed through telehealth consultations and administered at home, making it accessible to patients regardless of geographic location. The medication is shipped directly from compounding pharmacies.

Cost. This is typically the most affordable option, with monthly costs ranging from roughly $100 to $350 depending on the provider and dosing regimen. This makes ongoing maintenance therapy more financially sustainable for many patients.

Convenience. Treatments are completed at home according to a prescribed schedule, eliminating the need for clinic visits, travel, and transportation arrangements for each session. Sessions can be scheduled around the patient's own routine.

Non-invasive. No needles or clinical equipment are required, which some patients strongly prefer.

Disadvantages

Lower bioavailability. The significantly lower bioavailability means that a smaller and more variable proportion of the dose reaches the brain. This can result in less consistent and potentially less robust effects compared to IV infusion.

Less clinical evidence. While clinical use of oral and sublingual ketamine is growing rapidly, the published research base is smaller and less rigorous than for IV infusion. Most studies on oral formulations are observational rather than randomized controlled trials.

Variable absorption. Factors such as saliva production, how long the medication is held under the tongue, whether it is inadvertently swallowed, and individual metabolic differences can all affect how much ketamine is absorbed. This introduces variability that does not exist with IV delivery.

Reduced monitoring. At-home treatments may involve video monitoring by a telehealth provider, but this is not equivalent to in-person clinical monitoring with continuous vital sign tracking. Patients must have a sober adult present during sessions and follow specific safety protocols.

First-pass metabolism. Oral ketamine that is swallowed passes through the liver before reaching systemic circulation. The liver converts a significant portion of ketamine into norketamine, a metabolite that has some antidepressant activity but is less potent than ketamine itself.

Intranasal Ketamine (Spravato)

How It Works

Intranasal ketamine refers specifically to esketamine (Spravato), manufactured by Janssen Pharmaceuticals. Spravato contains only the S-enantiomer of ketamine and is FDA-approved for treatment-resistant depression and major depressive disorder with suicidal ideation. It is self-administered by the patient as a nasal spray under direct medical supervision in a certified healthcare setting.

The dosing protocol involves either 56 mg or 84 mg administered as multiple sprays, with the patient remaining in the clinic for at least two hours of post-dose monitoring.

Advantages

FDA approval. Spravato is the only ketamine-based medication with specific FDA approval for depression. This approval carries several practical benefits, including a standardized treatment protocol, established safety monitoring requirements, and pharmaceutical-grade manufacturing consistency.

Insurance coverage potential. Because Spravato has FDA approval, it is more likely to be covered by insurance plans compared to off-label IV or oral ketamine. With insurance, out-of-pocket costs may range from $0 to $200 per session, significantly lower than uninsured IV infusion costs.

Non-invasive delivery. The nasal spray is self-administered and does not require IV access, which some patients prefer.

REMS safety program. Spravato is administered under a Risk Evaluation and Mitigation Strategy (REMS) program, meaning it is only available through certified healthcare facilities. While this limits convenience, it ensures standardized safety monitoring.

Disadvantages

Cost without insurance. The list price of Spravato is approximately $600 to $900 per session. Without insurance coverage, the annual cost can exceed $15,000 to $30,000, making it the most expensive option for uninsured patients.

Restricted access. The REMS requirement means Spravato can only be administered at certified healthcare facilities. It cannot be taken at home. Patients must remain in the facility for at least two hours after each dose for observation.

Single enantiomer only. Spravato contains only S-ketamine, whereas most IV and oral formulations use racemic ketamine (containing both S- and R-ketamine). Some researchers believe that the R-ketamine component may contribute meaningfully to therapeutic effects. This remains an area of active investigation.

Nasal absorption variability. Congestion, sinusitis, recent nasal surgery, or improper administration technique can reduce absorption. Patients are instructed not to blow their nose for at least 20 minutes after dosing.

Prior authorization barriers. Most insurance plans require prior authorization and documented failure of two or more conventional antidepressants before approving Spravato coverage. The approval process can delay the start of treatment.

Head-to-Head Comparison

Effectiveness

Direct head-to-head clinical trials comparing all three methods in the same study are limited. For a more detailed pharmacological perspective on why these differences exist, see our ketamine pharmacology guide. Based on the available evidence:

IV infusion has the strongest and most consistent evidence for rapid antidepressant and anti-anxiety effects, supported by dozens of randomized controlled trials. Response rates for treatment-resistant depression range from approximately 50% to 70%.

Intranasal esketamine demonstrated efficacy in large phase III clinical trials that led to FDA approval. Response rates in pivotal trials were approximately 65% to 70% for treatment-resistant depression.

Oral and sublingual formulations have shown efficacy in observational studies and clinical practice, with response rates that appear broadly comparable to IV infusion, though the evidence quality is lower due to fewer controlled trials.

Cost Summary

Setting and Convenience

How to Choose the Right Method

The best administration method depends on several individual factors:

Choose IV infusion if you want the most evidence-backed approach with precise dosing, you have access to a ketamine infusion clinic within reasonable travel distance, cost is manageable or less of a concern, and you prefer the assurance of continuous in-person medical monitoring.

Choose intranasal esketamine if you have documented treatment-resistant depression, your insurance covers Spravato or you are eligible for patient assistance programs, you prefer an FDA-approved treatment with standardized protocols, and a certified REMS facility is accessible in your area.

Choose oral or sublingual ketamine if you value convenience and the ability to receive treatment at home, cost is a primary concern, you do not have convenient access to a ketamine clinic, your symptoms are stable enough for at-home treatment as determined by a provider, and you are comfortable with telehealth-based care and monitoring.

Many patients begin with one method and transition to another as their needs change. For example, starting with IV infusion for the initial treatment series and then transitioning to oral maintenance therapy is a common approach that balances the robust initial response of IV delivery with the convenience and affordability of at-home maintenance.

Combining Methods

Some treatment plans incorporate more than one method. A clinician might prescribe an initial series of IV infusions to establish a strong therapeutic response, then transition the patient to sublingual lozenges for ongoing maintenance. Alternatively, a patient on at-home oral ketamine might receive occasional IV "booster" infusions during periods of increased symptom severity.

These hybrid approaches leverage the strengths of each method while managing the practical limitations. Any combination should be coordinated by a single prescribing provider to ensure consistency and safety.

Important: The choice of ketamine delivery method should be made in consultation with a qualified healthcare provider who can evaluate your specific medical history, condition severity, practical circumstances, and treatment goals.

References

• StatPearls: Ketamine — Comprehensive clinical reference covering ketamine pharmacology including bioavailability data for multiple routes of administration
• FDA: Spravato (Esketamine) Prescribing Information — Official FDA labeling for intranasal esketamine including dosing protocols and REMS requirements
• Yanagihara Y, et al. (2003). Plasma Concentration Profiles of Ketamine and Norketamine After Administration of Various Ketamine Preparations. Biopharmaceutics and Drug Disposition — Pharmacokinetic study comparing bioavailability across ketamine administration routes
• NIMH: Mental Health Medications — National Institute of Mental Health information on psychiatric medications including emerging treatments
• Mayo Clinic: Treatment-Resistant Depression — Overview of treatment-resistant depression and available therapeutic approaches
• WHO Model List of Essential Medicines — World Health Organization essential medicines list including ketamine